Abstract
Purpose :
To investigate the effects of pro-resolution mediators Resolvin E1 (RvE1) on hypersensitivity responses in mice experimental allergic conjunctivitis (EAC) model.
Methods :
A murine model of EAC was induced in BALB/c, by injection of short ragweed pollen (SRW) followed by topical challenge of SRW daily. RvE1 was applied topically prior to SRW and phosphate buffer saline (PBS) as control. Clinical symptoms (N=6) were scored by slit lamp biomicroscope and mast cells and related immune cells infiltration were detected by Toluidine Blue O (N=6) and immune-staining (N=6). The percentage of Th1, Th2, Th17, and Treg cells in draining lymph nodes (DLNs) (N=8) were evaluated by flow cytometric analysis. The levels of Th2 and Th17-associated cytokines in the conjunctivitis were measured by cytometric bead array (N=6) and real-time PCR (N=4).
Results :
Topical RvE1 treatment significantly reduced symptoms of EAC. RvE1 treatment inhibition mast cell degranulation and dendritic cell migration in the conjunctivitis compared to the control group. After RvE1 treatment, the infiltration of related immune cells (Th2/Th17) cells were decreased in conjunctivitis. The mRNA expression of pro-inflammatory cytokines in the conjunctivitis including IL-4, IL-5, IL-13, IL-17A, IL-17F, IL-21, and IL-22 as well as the protein level of the pro-inflammatory cytokines, including IL-4, IL-5, IL-13,IL-17A were significantly reduced. However, RvE1 treatment did not alter the systemic type Th1, Th2, Th17, and Treg immune response in the DLNs.
Conclusions :
We conclude that topical application of RvE1 reduced the ocular allergic response via inhibition mast cell degranulation and DC cell migration and then depressed Th2/Th17-related immune response in local actions in conjunctivitis.
This is a 2020 ARVO Annual Meeting abstract.